(Q34476908)

2 August 2017

1 reference

title

A review of class III antiarrhythmic agents for atrial fibrillation: maintenance of normal sinus rhythm (English)

1 reference

2 August 2017

1 reference

J P Tsikouris

1

1 reference

2 August 2017

C D Cox

series ordinal

2

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 December 2001

1 reference

2 August 2017

1 reference

2 August 2017

volume

21

1 reference

2 August 2017

issue

12

1 reference

2 August 2017

page(s)

1514-1529

1 reference

Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study).

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1514.34484

Rhythm or rate control in atrial fibrillation--Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1514.34484

Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1514.34484

Atrial fibrillation: natural history, complications, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1514.34484

The coming of age of the class III antiarrhythmic principle: retrospective and future trends

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1514.34484

Antiarrhythmic drugs: a reorientation in light of recent developments in the control of disorders of rhythm

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1514.34484

Is hospital admission for initiation of antiarrhythmic therapy with sotalol for atrial arrhythmias required? Yield of in-hospital monitoring and prediction of risk for significant arrhythmia complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1514.34484

Factors influencing long term persistence of sinus rhythm after a first electrical cardioversion for atrial fibrillation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1514.34484

Pharmacologic and pharmacokinetic profile of class III antiarrhythmic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1514.34484

Amiodarone: Historical development and pharmacologic profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1514.34484

Amiodarone: electrophysiologic actions, pharmacokinetics and clinical effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1514.34484

Amiodarone blocks inactivated cardiac sodium channels

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1514.34484

The historical development, cellular electrophysiology and pharmacology of amiodarone

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1514.34484

Clinical efficacy and electrophysiology during long-term therapy for recurrent ventricular tachycardia or ventricular fibrillation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1514.34484

Antiarrhythmic actions of amiodarone: a profile of a paradoxical agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1514.34484

Atypical ventricular tachycardia (torsade de pointes) induced by amiodarone: arrhythmia previously induced by quinidine and disopyramide

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1514.34484

Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1514.34484

A dose-ranging study of UK-68,798, a novel class III anti-arrhythmic agent, in normal volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1514.34484

Pharmacology, pharmacodynamics and pharmacokinetics of sotalol

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1514.34484

Pharmacokinetics of the -adrenergic blocker sotalol in dogs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1514.34484

Absolute bioavailability of amiodarone in normal subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1514.34484

Amiodarone and its desethyl metabolite: tissue distribution and morphologic changes during long-term therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1514.34484

The dilemma of the prolonged QT interval in early drug studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1514.34484

Low-dose amiodarone versus sotalol for suppression of recurrent symptomatic atrial fibrillation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1514.34484

Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1514.34484

Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1514.34484

Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1514.34484

Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1514.34484

Side effects and complications of amiodarone therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1514.34484

Very early onset of acute amiodarone pulmonary toxicity presenting with hemoptysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1514.34484

The novel class III antiarrhythmics NE-10064 and NE-10133 inhibit IsK channels expressed in Xenopus oocytes and IKs in guinea pig cardiac myocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1514.34484

Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1514.34484

Atrial fibrillation as a self-sustaining arrhythmia independent of focal discharge

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.20.1514.34484

10.1592/PHCO.21.20.1514.34484

21 January 2018

Identifiers

DOI

1 reference

2 August 2017

1 reference